Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicinium ®, also known as VB4-845 ...

Sesen Bio SESN is expected to provide an update on its restructuring and strategic initiatives when it reports second-quarter 2022 results The late-stage clinical company beat earnings expectations in ...

Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China, the Middle East and North Africa (MENA) and Turkey, for which the Company has partnered with Qilu Pharmaceutical, ...

Philadelphia, Pennsylvania--(Newsfile Corp. - September 29, 2021) - Berger Montague is investigating securities fraud allegations against Sesen Bio, Inc. ("Sesen" or the "Company"). The Firm is ...

After a brutal 2021 that included an FDA rejection reportedly stemming from trial misconduct, Sesen Bio is looking for an exit route, including a possible sale. The about-face, announced Tuesday, is a ...

Shares of Sesen Bio Inc. SESN were trading sharply higher following a company announcement that the FDA granted its request for a Type A Meeting to discuss the issues brought up within the complete ...

Product market application expected to be submitted to the National Medical Products Administration in 2022 with potential approval in 2023 COVID-19 Pandemic Potential Impact Sesen Bio continues to ...

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Sesen Bio (NASDAQ:SESN) has seen its share price rise 472% over the last year, delighting many ...

Sesen Bio Inc (NASDAQ:SESN) shares are trading higher by 16.81% to $0.59 Friday morning after the company and Carisma Therapeutics announced an increased special dividend of $70 million, or $0.34 per ...

Sesen Bio (NASDAQ:SESN) investors reiterated their plan to vote against the merger with Carisma Therapeutics, calling it an "illogical, value-destructive" deal. Sesen rose 4.2%. Bradley L. Radoff and ...

The Company believes it remains on track for an FDA decision on its BLA for Vicineum by August 18, 2021 “At Sesen Bio, we believe a strong culture of compliance is a source of competitive advantage, ...